CIGNA Co. (NYSE:CI) Director Sells $43,604.16 in Stock

CIGNA Co. (NYSE:CI) Director William D. Zollars sold 212 shares of the company’s stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $205.68, for a total value of $43,604.16. Following the completion of the sale, the director now owns 13,500 shares in the company, valued at approximately $2,776,680. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

CIGNA Co. (NYSE:CI) traded down $8.05 on Monday, hitting $196.41. The stock had a trading volume of 2,223,692 shares, compared to its average volume of 1,469,275. CIGNA Co. has a 1-year low of $141.93 and a 1-year high of $227.13. The stock has a market capitalization of $49,910.00, a price-to-earnings ratio of 21.51, a P/E/G ratio of 1.30 and a beta of 0.44. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.39 and a current ratio of 0.37.

CIGNA (NYSE:CI) last released its quarterly earnings results on Thursday, February 1st. The health services provider reported $1.94 EPS for the quarter, topping the consensus estimate of $1.87 by $0.07. The business had revenue of $10.53 billion during the quarter, compared to analyst estimates of $10.28 billion. CIGNA had a return on equity of 18.84% and a net margin of 5.38%. The company’s quarterly revenue was up 5.9% on a year-over-year basis. During the same period last year, the business posted $1.87 earnings per share. research analysts expect that CIGNA Co. will post 12.42 earnings per share for the current year.

A number of equities analysts have issued reports on CI shares. Morgan Stanley increased their price target on CIGNA to $255.00 and gave the stock an “overweight” rating in a research report on Friday. Royal Bank of Canada reiterated an “outperform” rating and set a $220.00 price target (up previously from $185.00) on shares of CIGNA in a research report on Friday, November 3rd. Credit Suisse Group initiated coverage on CIGNA in a research report on Thursday, November 2nd. They set an “outperform” rating and a $219.00 price target on the stock. Oppenheimer increased their target price on CIGNA to $237.00 and gave the company an “outperform” rating in a report on Friday. Finally, Goldman Sachs Group initiated coverage on CIGNA in a report on Wednesday, January 3rd. They set a “neutral” rating and a $247.00 target price for the company. Three investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $210.12.

A number of large investors have recently added to or reduced their stakes in CI. Investec Asset Management LTD boosted its holdings in CIGNA by 35.4% in the third quarter. Investec Asset Management LTD now owns 1,849,598 shares of the health services provider’s stock valued at $345,764,000 after purchasing an additional 483,904 shares during the period. FMR LLC boosted its holdings in CIGNA by 6.7% in the second quarter. FMR LLC now owns 6,909,638 shares of the health services provider’s stock valued at $1,156,604,000 after purchasing an additional 432,978 shares during the period. Arrowstreet Capital Limited Partnership boosted its holdings in CIGNA by 4,082.8% in the second quarter. Arrowstreet Capital Limited Partnership now owns 438,231 shares of the health services provider’s stock valued at $73,355,000 after purchasing an additional 427,754 shares during the period. Vanguard Group Inc. boosted its holdings in CIGNA by 2.5% in the second quarter. Vanguard Group Inc. now owns 17,130,735 shares of the health services provider’s stock valued at $2,867,514,000 after purchasing an additional 424,469 shares during the period. Finally, APG Asset Management N.V. boosted its holdings in CIGNA by 148.4% in the fourth quarter. APG Asset Management N.V. now owns 670,299 shares of the health services provider’s stock valued at $113,367,000 after purchasing an additional 400,473 shares during the period. Hedge funds and other institutional investors own 88.04% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/05/william-d-zollars-sells-212-shares-of-cigna-co-ci-stock.html.

About CIGNA

Cigna Corporation (Cigna), together with its subsidiaries, is a health services company. The Company offers medical, dental, disability, life and accident insurance and related products and services. The Company’s segments include Global Health Care, Global Supplemental Benefits, Group Disability and Life, and Other Operations and Corporate.

Insider Buying and Selling by Quarter for CIGNA (NYSE:CI)

Receive News & Ratings for CIGNA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CIGNA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply